Journal article icon

Journal article

Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children.

Abstract:
An open, randomised comparison of 2 or 3 days of oral ofloxacin (10 mg/kg/day) for uncomplicated typhoid fever was conducted in 235 Vietnamese children. Multi-drug-resistant Salmonella typhi was isolated from 182/202 (90%) children and 5/166 (3%) tested isolates were nalidixic acid-resistant (Na(R)). Eighty-nine of 116 children randomised to 2 days and 107/119 randomised to 3 days were blood culture-positive and eligible for analysis. There were 12 (13.5%) failures in the 2-day group (six clinical failures, four blood culture-positive post treatment, two relapses) compared with eight (7.5%) failures in the 3-day group (four clinical failures, one blood culture-positive post treatment, three relapses) (OR 1.9, 95% CI 0.7-5.5,p = 0.17). There were no significant differences in the mean (95% confidence interval) fever clearance times (h) [92 (82-102) vs 101 (93-110), p = 0.18] or duration of hospitalisation (d) [7.6 (7.2-8.1) vs 8.0 (7.6-8.4), p = 0.19] between the two groups. There was one failure in the four eligible children infected with an Na(R) isolate of S. typhi. No adverse events were attributable to the ofloxacin. These results extend previous observations on the efficacy of short courses of ofloxacin for children with uncomplicated multi-drug-resistant typhoid fever.
Publication status:
Published

Actions

Access Document

Publisher copy:
10.1179/146532805x23308

Authors


Journal:
Annals of tropical paediatrics More from this journal
Volume:
25
Issue:
1
Pages:
17-22
Publication date:
2005-03-01
DOI:
EISSN:
1465-3281
ISSN:
0272-4936


Language:
English
Keywords:
Pubs id:
pubs:39401
UUID:
uuid:136ad7c5-4299-4bda-bcaf-17426f965d60
Local pid:
pubs:39401
Source identifiers:
39401
Deposit date:
2012-12-19
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP